AMF Tjanstepension AB boosted its stake in Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 26.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,341 shares of the biotechnology company’s stock after buying an additional 7,233 shares during the period. AMF Tjanstepension AB’s holdings in Axon Enterprise were worth $10,745,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Axon Enterprise by 4.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 7,519 shares of the biotechnology company’s stock valued at $2,353,000 after purchasing an additional 319 shares during the period. Brookstone Capital Management grew its holdings in Axon Enterprise by 5.1% during the first quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company’s stock worth $263,000 after acquiring an additional 41 shares during the period. First PREMIER Bank acquired a new position in Axon Enterprise during the first quarter worth about $33,000. Ballentine Partners LLC acquired a new position in Axon Enterprise during the first quarter worth about $216,000. Finally, Gulf International Bank UK Ltd grew its holdings in Axon Enterprise by 1.5% during the first quarter. Gulf International Bank UK Ltd now owns 5,843 shares of the biotechnology company’s stock worth $1,828,000 after acquiring an additional 86 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. Needham & Company LLC reissued a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a research note on Tuesday, May 7th. Morgan Stanley lifted their price target on Axon Enterprise from $285.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, April 26th. StockNews.com lowered Axon Enterprise from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. Finally, JMP Securities restated a “market outperform” rating and set a $375.00 price objective on shares of Axon Enterprise in a research report on Tuesday, May 7th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $335.27.
View Our Latest Report on Axon Enterprise
Axon Enterprise Stock Down 1.4 %
AXON opened at $294.24 on Friday. The business has a 50 day moving average price of $295.25 and a 200 day moving average price of $284.70. Axon Enterprise, Inc. has a twelve month low of $175.37 and a twelve month high of $329.87. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91. The firm has a market cap of $22.21 billion, a P/E ratio of 86.04 and a beta of 0.91.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.20. The firm had revenue of $460.74 million during the quarter, compared to analyst estimates of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The company’s revenue for the quarter was up 34.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.51 EPS. Research analysts forecast that Axon Enterprise, Inc. will post 2.35 EPS for the current year.
Insiders Place Their Bets
In other Axon Enterprise news, Director Jeri Williams sold 308 shares of the business’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total value of $95,501.56. Following the transaction, the director now owns 1,607 shares of the company’s stock, valued at $498,282.49. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Jeri Williams sold 308 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the transaction, the director now owns 1,607 shares of the company’s stock, valued at $498,282.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Julie A. Cullivan sold 993 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $281.72, for a total value of $279,747.96. Following the transaction, the director now directly owns 4,553 shares in the company, valued at approximately $1,282,671.16. The disclosure for this sale can be found here. Insiders have sold a total of 89,447 shares of company stock valued at $27,684,677 in the last three months. Company insiders own 6.10% of the company’s stock.
Axon Enterprise Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Stories
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.
